Key result
Single-sample rule-out of NSTEMI using high-sensitivity cardiac troponin T remains clinically safe despite high analytical imprecision.
Why the study?
Why is single sample rule out of non-ST elevation myocardial infarction using high-sensitivity cardiac troponin T safe when analytical imprecision is high?
Why is single sample rule out of non-ST elevation myocardial infarction using high-sensitivity cardiac troponin T safe when analytical imprecision is high?
This paper provides a joint statistical and clinical demonstration explaining the safety of single-sample rule-out for NSTEMI using hs-cTnT despite high analytical imprecision.
Single-sample hs-cTnT rule-out for NSTEMI remains statistically viable despite imprecision; leaves open need for prospective outcome validation before broader adoption.
Article Why is single sample rule out of non-ST elevation myocardial infarction using high-sensitivity cardiac troponin T safe when analytical imprecision is so high? A joint statistical and clinical demonstration was published on February 1, 2025 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 63, issue 3).
No takes yet. Share an insight, caveat, or question.
Hatherley et al. (2024) studied this question. Single-sample rule-out of NSTEMI using high-sensitivity cardiac troponin T remains clinically safe despite high analytical imprecision.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: